CeriBell (NASDAQ:CBLL) Director William Burke Sells 18,000 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) Director William Burke sold 18,000 shares of the firm’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $26.64, for a total value of $479,520.00. Following the completion of the sale, the director owned 23,022 shares of the company’s stock, valued at approximately $613,306.08. This represents a 43.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

CeriBell Stock Down 0.8%

CeriBell stock traded down $0.21 during midday trading on Friday, reaching $26.14. The stock had a trading volume of 267,634 shares, compared to its average volume of 372,668. The company has a fifty day moving average price of $25.49 and a two-hundred day moving average price of $21.02. CeriBell, Inc. has a 12 month low of $12.40 and a 12 month high of $28.89. The company has a current ratio of 8.18, a quick ratio of 7.79 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $1.02 billion, a P/E ratio of -13.47 and a beta of 0.86.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). CeriBell had a negative return on equity of 52.59% and a negative net margin of 67.96%. The firm had revenue of $29.34 million during the quarter, compared to the consensus estimate of $29.18 million. As a group, equities analysts expect that CeriBell, Inc. will post -2.05 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Legal & General Group Plc bought a new position in CeriBell during the 2nd quarter valued at $53,000. State of Wyoming purchased a new position in CeriBell during the 1st quarter worth $62,000. Quantbot Technologies LP purchased a new position in CeriBell during the 2nd quarter worth $112,000. Principal Financial Group Inc. grew its stake in shares of CeriBell by 71.9% in the 1st quarter. Principal Financial Group Inc. now owns 23,180 shares of the company’s stock worth $425,000 after acquiring an additional 9,696 shares in the last quarter. Finally, Formula Growth Ltd. bought a new stake in shares of CeriBell in the 2nd quarter worth $603,000.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. Canaccord Genuity Group boosted their price target on shares of CeriBell from $26.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, November 4th. TD Cowen upped their price objective on shares of CeriBell from $29.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, October 2nd. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $29.00 price objective on shares of CeriBell in a research note on Thursday, September 3rd. Finally, BTIG Research reiterated a “buy” rating on shares of CeriBell in a report on Wednesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $31.25.

CeriBell Company Profile

Ceribell, Inc. develops neurodiagnostic technology for detecting and monitoring seizures. Its products are designed to make electroencephalography (EEG) more accessible in emergency departments and intensive care units, where timely assessment can be important and conventional EEG services may not be readily available. The company’s Ceribell point-of-care EEG system combines a headband with electrodes, a portable recorder and software for viewing and analyzing EEG data. Its Clarity algorithm is designed to help clinicians identify patterns associated with seizure activity, while the system supports remote review by specialists.